Helixgate https://validator.w3.org/feed/docs/rss2.html Home Scientific Advisory Board From Colossal to Chickens: The Scientists Behind Neion Bio’s Biologics Platform Lilly investing billions to prepare for overseas oral GLP-1 launches Lilly wants to bridge cancer care gap with $300M ADC biotech buy STAT+: Hospitals offer chatbots to fight off ChatGPT STAT+: Pharmalittle: We’re reading about an FDA push for trial transparency, a Novo-OpenAI deal, and more Eli Lilly to pay up to $300M for cancer biotech CrossBridge Bio A fluoride shortage for some U.S. water systems  Parker Institute doubles down on cancer vaccines as part of ongoing reboot FDA approves Travere’s Filspari as first drug for the kidney disease called FSGS STAT+: Dana-Farber CEO talks untangling from Mass General Brigham and building new cancer hospital A top WHO official confronts Iran war fallout, and weighs bid for an even bigger role STAT+: Maryland state affordability board sets its first price cap for a medicine StockWatch: IPO Market Shows Sign of Life with Avalyn Filing STAT+: FDA pushes drugmakers to report missing clinical trial results STAT+: Federal judge tosses California No Surprises Act lawsuit against HaloMD Click Therapeutics cuts 27% of workforce after $50M raise Sex-Related Differences in Immune System Aging May Impact Disease Susceptibility White House policies are ‘incredibly worrisome’ for small biotechs, Rhythm CEO says  STAT+: Access granted: CMS greenlights more than 150 participants for chronic care experiment FDA narrows in on search for new biologics and vaccines leader Press Footer GSK plans five Phase 3 studies for gynecological cancer ADC from Hansoh Spyre drug for inflammatory bowel disease shows promise in early study Regeneron wades into radiopharma through $40M upfront deal with Telix Neural Mechanism Underlying Sensory Behavior Revealed in C. elegans FDA urges clinical trial sponsors to report the results of their studies ReAlta secures $40m to advance peptide for newborn brain injury STAT+: GSK advancing ovarian cancer drug mo-rez Light makes plants stronger but also holds them back Revolution Medicines’ pancreatic cancer drug doubles survival time in Phase 3 STAT+: Revolution Medicines touts ‘unprecedented’ data for pancreatic cancer pill Second rejection for tumor destroyer puts Replimune on a ‘challenging path’ STAT+: Allogene Therapeutics’ CAR-T treatment eliminates residual cancer cells in B-cell lymphoma patients Life on Mars? Tiny cells just survived shock waves and toxic soil Opinion: Sports betting is creating a twofold public health crisis for some young men Ideaya’s uveal melanoma drug exceeds success benchmark in late-stage trial Rethinking dermatology trial design for late-stage success STAT+: Hospitals roll out chatbots, looking to reclaim their role in patients’ health conversations Seaport and Hemab file for IPOs, with Kailera expected to price soon Design of the biosensor-dependent coupling system stabilizes the high-synthesis phenotype of cell factory Solar-driven biosynthesis of chemicals from phosphite-rich wastewater and carbon dioxide Hydrophobic tuning with non-canonical amino acids in a copper metalloenzyme Opinion: What STAT readers think about nutrition education in med school Revolution pancreatic cancer drug nearly doubles survival in key trial More pharma dealmaking; FDA’s proposed budget; Takeda ends partnership; and more A synthetic angiotensin II/ACE2-based hormone shunt controlling experimental hypertension Allogene’s first cut of data on ‘off-the-shelf’ CAR-T shows promise